New Drug Carrimycin
Carrimycin is tongliangroup latest technology and product contribution to global public health and life health. Based on the long-term research results of genetic engineering drugs, our scientists have successfully developed Chinese Class 1.1 innovative drugs with clinical application value using "synthetic biology technology" for the first time in the world.
We are committed to relieving the disease and suffering of TB patients who account for one-third of the world's total population. We have worked closely with scientists, medical scientists, and doctors to develop and produce Rifampicin, the first-line drug of choice for treating tuberculosis.
Continuously improve the value of human life
Scientific and Technological Association, Cultural Association, and Quality Association
Create an innovative world-class new association with high-tech content, high cultural added value, and high market share.